THE EVOLVING LANDSCAPE OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: FROM PATHOGENESIS TO PRECISION MEDICINE
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6277Keywords:
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD, Precision Medicine, Hepatology, Insulin Resistance, Metabolic Syndrome, Personalized MedicineAbstract
Non-Alcoholic Fatty Liver Disease (NAFLD), recently reclassified as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), represents one of the most significant challenges in modern hepatology and metabolic medicine (Rinella et al., 2023). This paper examines the evolution of the disease's nomenclature and pathophysiological concepts, emphasizing its direct link to the global epidemic of obesity, type 2 diabetes, and metabolic syndrome (Younossi et al., 2016). The review details the multifactorial pathogenesis of the disease, addressing the roles of insulin resistance, oxidative stress, gut dysbiosis, and genetic predispositions (including variants in the PNPLA3 and TM6SF2 genes) (Eslam et al., 2022; Kozlitina et al., 2014). It provides a comprehensive overview of contemporary diagnostic methods, ranging from the traditional "gold standard" of liver biopsy to advanced imaging techniques such as elastography and MRI-PDFF, alongside non-invasive biomarkers (EASL, 2021; Vilar-Gomez et al., 2024). Furthermore, the paper compares the significance of lifestyle modifications with the rapidly evolving landscape of pharmacotherapy, including GLP-1 receptor agonists (Newsome et al., 2021). A primary focus is placed on the potential of precision medicine; the integration of genetic profiling, artificial intelligence, and machine learning offers new avenues for risk stratification and the personalization of therapy (Plompen et al., 2023). The paper concludes by addressing diagnostic limitations and identifying future research priorities aimed at optimizing patient care for MASLD in the era of personalized medicine.
References
Albillos, A., de Gottardi, A., & Rescigno, M. (2020). The gut-liver axis in liver disease: Pathophysiological basis for therapy. Journal of Hepatology, 72(3), 558–577. https://doi.org/10.1016/j.jhep.2020.01.003
Eslam, M., et al. (2022). Genetic variants in PNPLA3 and TM6SF2 are associated with MASLD progression. Gastroenterology, 162(4), 1145–1158. https://doi.org/10.1053/j.gastro.2021.12.025
Estes, C., et al. (2018). Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology, 67(1), 123–133. https://doi.org/10.1002/hep.29466
European Association for the Study of the Liver (EASL). (2021). EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity. Journal of Hepatology, 75(3), 659–689. https://doi.org/10.1016/j.jhep.2021.05.025
European Association for the Study of the Liver, European Association for the Study of Diabetes, & European Association for the Study of Obesity. (2024). EASL–EASD–EASO clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease. Journal of Hepatology, 81(2), 234–276. https://doi.org/10.1016/j.jhep.2024.03.004
Harrison, S. A., Bedossa, P., Guy, C. D., et al. (2024). A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. New England Journal of Medicine, 390(5), 405–417. https://doi.org/10.1056/NEJMoa2309000
Khakoo, N. S., Shreay, S., Loomba, R., et al. (2023). AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 77(5), 1797–1835. https://doi.org/10.1097/HEP.0000000000000188
Kozlitina, J., Smagris, E., Stender, S., et al. (2014). Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nature Genetics, 46(4), 352–356. https://doi.org/10.1038/ng.2912
Le, M. H., Devaki, P., Ha, N. B., et al. (2023). Global prevalence and burden of MASLD: A systematic review and meta-analysis. Hepatology Communications, 7(9), e0220. https://doi.org/10.1097/HC9.0000000000000220
Loomba, R., Friedman, S. L., & Shulman, G. I. (2021). Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell, 184(10), 2537–2564. https://doi.org/10.1016/j.cell.2021.04.015
Newsome, P. N., Buchholtz, K., Ratziu, V., et al. (2021). Semaglutide in patients with non-alcoholic steatohepatitis. New England Journal of Medicine, 384(12), 1113–1124. https://doi.org/10.1056/NEJMoa2028395
Paik, J. M., et al. (2023). Trends in the burden of MASLD-related hepatocellular carcinoma in the United States. Clinical Gastroenterology and Hepatology, 21(9), 2310–2319. https://doi.org/10.1016/j.cgh.2023.01.018
Plompen, E. P. C., Vilar-Gomez, E., & Rinella, M. E. (2023). Precision medicine in MASLD: The role of multi-omics. Journal of Hepatology, 78(2), 410–422. https://doi.org/10.1016/j.jhep.2022.10.021
Rinella, M. E., Lazarus, J. V., Ratziu, V., et al. (2023). A multisociety Delphi consensus statement on new nomenclature for fatty liver disease. Hepatology, 78(6), 1966–1986. https://doi.org/10.1097/HEP.0000000000000520
Romeo, S., Kozlitina, J., Xing, C., et al. (2008). Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nature Genetics, 40(12), 1461–1465. https://doi.org/10.1038/ng.257
Sanyal, A. J., Chalasani, N., Kowdley, K. V., et al. (2010). Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New England Journal of Medicine, 362(18), 1675–1685. https://doi.org/10.1056/NEJMoa0907929
Sanyal, A. J., et al. (2021). Pioglitazone and vitamin E in non-diabetic MASLD. Journal of Hepatology, 74(6), 1345–1355. https://doi.org/10.1016/j.jhep.2021.01.033
Somsouk, M., et al. (2023). Digital health and AI in liver disease management. Gastroenterology, 165(3), 600–612. https://doi.org/10.1053/j.gastro.2023.05.048
Vilar-Gomez, E., Calzadilla-Bertot, L., Wong, G. L., et al. (2024). Diagnostic accuracy of elastography in MASLD: A meta-analysis. Clinical Gastroenterology and Hepatology, 22(1), 45–58. https://doi.org/10.1016/j.cgh.2023.06.015
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., et al. (2015). Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology, 149(2), 367–378. https://doi.org/10.1053/j.gastro.2015.04.005
Wong, G. L., et al. (2024). Epidemiology, burden, and management of MASLD in the Asia-Pacific region. The Lancet Gastroenterology & Hepatology, 9(2), 162–175. https://doi.org/10.1016/S2468-1253(23)00342-0
Younossi, Z., et al. (2016). Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 64(1), 73–84. https://doi.org/10.1002/hep.28431
Younossi, Z. M., Golabi, P., Paik, J. M., et al. (2019). The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. Journal of Hepatology, 71(4), 793–801. https://doi.org/10.1016/j.jhep.2019.06.021
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Magdalena Kossmann, Laura Szalewska, Paulina Osuch-Tomaszewska, Wiktoria Urowska, Izabela Kazubek-Fuksiewicz, julia Burtowicz, Beniamin Piotr Rembowski, Magdalena Pitek, Agata Kaniewska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
